Your browser doesn't support javascript.
loading
Stroke Update 2011: New Antithrombotics / 대한뇌졸중학회지
Korean Journal of Stroke ; : 62-66, 2012.
Article in Korean | WPRIM | ID: wpr-14871
ABSTRACT
Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Propionates / Pyrazoles / Pyridines / Pyridones / Atrial Fibrillation / Thiophenes / Benzimidazoles / Thrombin / Factor Xa / Aspirin Type of study: Incidence study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: Korean Journal: Korean Journal of Stroke Year: 2012 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Propionates / Pyrazoles / Pyridines / Pyridones / Atrial Fibrillation / Thiophenes / Benzimidazoles / Thrombin / Factor Xa / Aspirin Type of study: Incidence study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: Korean Journal: Korean Journal of Stroke Year: 2012 Type: Article